While I don’t find this surprising, it underscores the power of modern pharmacology. Many drugs deliver only incremental improvement, but semaglutide–like anti-hypertensives and statins–looks transformative for many people.“The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial, potentially expanding the already wildly popular drug’s use beyond diabetes and weight loss and offering a new treatment option where few are available.“The study of 529 patients, funded by drugmaker Novo Nordisk, found that a 2.4-milligram weekly dose of semaglutide, sold as Wegovy for weight loss, led to an improvement of 17 points on a
Topics:
Joel Eissenberg considers the following as important: Healthcare, Hot Topics, semaglutide
This could be interesting, too:
NewDealdemocrat writes The Household Survey isn’t the only data series sending up caution flares
Joel Eissenberg writes Is China eating our EV lunch?
Angry Bear writes Clawback of money looted by Cerberus, de la Torre, and MPT from Steward Health Care
NewDealdemocrat writes Initial claims jolted awake from snooze-fest by highest number in almost nine months
While I don’t find this surprising, it underscores the power of modern pharmacology. Many drugs deliver only incremental improvement, but semaglutide–like anti-hypertensives and statins–looks transformative for many people.
“The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial, potentially expanding the already wildly popular drug’s use beyond diabetes and weight loss and offering a new treatment option where few are available.
“The study of 529 patients, funded by drugmaker Novo Nordisk, found that a 2.4-milligram weekly dose of semaglutide, sold as Wegovy for weight loss, led to an improvement of 17 points on a 100-point scale that’s used to assess symptoms of a condition known as heart failure with preserved ejection fraction. By comparison, participants who got a placebo had a 9-point improvement. The study was published Friday in the New England Journal of Medicine.”